Patients stressed, anxious about treatment decisions: study
A new report has revealed that many patients living with inflammatory diseases lack the critical information necessary to be able to properly understand and evaluate their treatment options.
More than two million Canadians are living with inflammatory diseases such as ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis.
The Biosimilar Focus Group Project Report, prepared by a group of patient advocacy organizations representing Canadians living with inflammatory disease, highlights the need for more education and patient support in the treatment decision-making process for people living with inflammatory disease.
Through a series of focus groups, the project set out to understand patients' experience and perception of biologic medications; to evaluate their awareness and understanding of biosimilars; and to identify any implications and issues arising related to a change in medication, including switching from a biologic to a biosimilar.
"The arrival of biosimilars in the Canadian market is creating pressure for changes in the way inflammatory disease treatments are selected and paid for," explained Janet Yale, president and CEO of The Arthritis Society. "This report aims to help inform decision makers and health care providers alike about the experiences of people living with inflammatory disease, so they can consider the needs of those patients in any decisions around access to these treatments, and the supports that may be required."
Focus group participants had all been on more than one biologic already in their treatment journey, and their experience and perspective proved very important in informing the findings.
"Whether you are newly diagnosed with an inflammatory disease or someone who has gone through a number of treatments, it is important to be informed about the options available," said Mina Mawani, president and CEO of Crohn's and Colitis Canada.
"Understanding what is available can alleviate anxiety and provide hope for the many people living with chronic diseases. The focus group results underscore the need for more education about treatment options – and more engagement and involvement in the treatment decision process for patients," she added.
Some of the key findings from the study include:
Need for education. More education and awareness is needed around treatment options. Participants showed a general lack of understanding of the health-care process and the treatment options available to them for their inflammatory disease, and in particular a poor understanding of biologics and biosimilars.
Emotional impact. Patients experience a high degree of emotional impact from their inflammatory disease journey, from delays in diagnosis and access to treatment, to considerable uncertainty throughout the journey. Better resources and support are needed to help them cope with the non-physical impacts of their diseases.
Switching to biosimilars. One aspect of those impacts relates to stress and anxiety associated with switching medications. Participants were open to the role of biosimilars for new patients who had not been on the originator biologic, but were strongly opposed to the idea of people who are currently stable on an originator biologic being switched to a biosimilar for non-medical reasons, until research could determine that it was safe and effective. There was also a concern expressed that switching would reopen access and coverage questions for patients.
Partners in the treatment decision process. All treatment decisions need to be made by the patient and physician together based on the clinical evidence and the best interests of the individual patient. Patients want to be better informed, more empowered and involved in the treatment decision process, and want to be better connected to sources of support.
A 'new normal.' Patients don't expect a silver bullet; they are just looking to achieve 'new normal' of symptom and treatment stability that allows them to carry on with their lives.
Support for PSPs. Patient support programs (PSPs) provided by the manufacturers of their current medications are highly valued by patients. There were concerns that switching to a biosimilar might eliminate access to this kind of program.
The six diseases covered by the report, including ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, are autoimmune conditions accompanied by inflammation, and collectively affect the lives of 2.25 million Canadians. While they manifest differently, these diseases share many similarities: their causes are unknown; there is no known cure or prevention strategy; all are prone to episodic, unpredictable flares; and while effective treatments are available, they are complex, and response varies by individual.
The study was led by The Arthritis Society in collaboration with Canadian Arthritis Patient Alliance, Canadian Psoriasis Network, Crohn's and Colitis Canada, and the Gastrointestinal Society.
The RMTAO and CMTO relationshipAs a massage therapist, I appreciate and benefit from the…
Doctors urge better access to alternative treatments to reduce opioid useAn addictions doctor in Saskatchewan says physicians need more help…
Headache? Let your hair downIf you've ever weaved your hair into a tight braid,…
5 potential hidden costs of your social media campaignFor many business owners, the lure of social media is…
EXSTORE Functional Assessment and Soft-Tissue Treatment workshop
October 28-29, 2017